Which has higher earnings and valuation, GYRE or HCM?

HUTCHMED has higher revenue and earnings than Gyre Therapeutics. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Gyre Therapeutics $116.59M 5.15 $5.03M -$0.09 N/A HUTCHMED $548.51M 3.55 $456.91M N/A N/A

Gyre Therapeutics (GYRE) Competitors

$6.19 +0.50 (+8.79%)

Closing price 04:00 PM Eastern

Extended Trading

$6.19 0.00 (0.00%)

As of 06:38 PM Eastern

Compare

GYRE vs. RARE, RXRX, HCM, BHC, and TRVI

Should you buy Gyre Therapeutics stock or one of its competitors? MarketBeat compares Gyre Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Gyre Therapeutics include Ultragenyx Pharmaceutical (RARE), Recursion Pharmaceuticals (RXRX), HUTCHMED (HCM), Bausch Health Cos (BHC), and Trevi Therapeutics (TRVI). These companies are all part of the "pharmaceutical products" industry.

How does Gyre Therapeutics compare to Ultragenyx Pharmaceutical?

Ultragenyx Pharmaceutical (NASDAQ:RARE) and Gyre Therapeutics (NASDAQ:GYRE) are both medical companies, but which is the better business? We will contrast the two companies based on the strength of their media sentiment, risk, profitability, earnings, dividends, analyst recommendations, valuation and institutional ownership.

97.7% of Ultragenyx Pharmaceutical shares are owned by institutional investors. Comparatively, 24.0% of Gyre Therapeutics shares are owned by institutional investors. 5.2% of Ultragenyx Pharmaceutical shares are owned by insiders. Comparatively, 9.5% of Gyre Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Gyre Therapeutics has lower revenue, but higher earnings than Ultragenyx Pharmaceutical. Gyre Therapeutics is trading at a lower price-to-earnings ratio than Ultragenyx Pharmaceutical, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ultragenyx Pharmaceutical	$673M	3.41	-$575M	-$6.11	N/A
Gyre Therapeutics	$116.59M	5.15	$5.03M	-$0.09	N/A

In the previous week, Ultragenyx Pharmaceutical had 6 more articles in the media than Gyre Therapeutics. MarketBeat recorded 6 mentions for Ultragenyx Pharmaceutical and 0 mentions for Gyre Therapeutics. Gyre Therapeutics' average media sentiment score of 1.87 beat Ultragenyx Pharmaceutical's score of 0.50 indicating that Gyre Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Ultragenyx Pharmaceutical	Positive
Gyre Therapeutics	Very Positive

Ultragenyx Pharmaceutical has a beta of 0.37, suggesting that its stock price is 63% less volatile than the broader market. Comparatively, Gyre Therapeutics has a beta of 1.9, suggesting that its stock price is 90% more volatile than the broader market.

Gyre Therapeutics has a net margin of -5.44% compared to Ultragenyx Pharmaceutical's net margin of -91.03%. Gyre Therapeutics' return on equity of 3.13% beat Ultragenyx Pharmaceutical's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Ultragenyx Pharmaceutical	-91.03%	-1,024.42%	-45.78%
Gyre Therapeutics	-5.44%	3.13%	2.67%

Ultragenyx Pharmaceutical currently has a consensus price target of $59.56, indicating a potential upside of 155.52%. Gyre Therapeutics has a consensus price target of $17.00, indicating a potential upside of 174.64%. Given Gyre Therapeutics' higher probable upside, analysts clearly believe Gyre Therapeutics is more favorable than Ultragenyx Pharmaceutical.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ultragenyx Pharmaceutical	1 Sell rating(s)	2 Hold rating(s)	13 Buy rating(s)	1 Strong Buy rating(s)	2.82
Gyre Therapeutics	2 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.00

Summary

Gyre Therapeutics beats Ultragenyx Pharmaceutical on 10 of the 17 factors compared between the two stocks.

How does Gyre Therapeutics compare to Recursion Pharmaceuticals?

Gyre Therapeutics (NASDAQ:GYRE) and Recursion Pharmaceuticals (NASDAQ:RXRX) are both medical companies, but which is the better business? We will contrast the two companies based on the strength of their valuation, risk, dividends, analyst recommendations, profitability, institutional ownership, media sentiment and earnings.

Gyre Therapeutics has higher revenue and earnings than Recursion Pharmaceuticals. Gyre Therapeutics is trading at a lower price-to-earnings ratio than Recursion Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Gyre Therapeutics	$116.59M	5.15	$5.03M	-$0.09	N/A
Recursion Pharmaceuticals	$74.68M	26.96	-$644.76M	-$1.20	N/A

Gyre Therapeutics currently has a consensus target price of $17.00, indicating a potential upside of 174.64%. Recursion Pharmaceuticals has a consensus target price of $8.10, indicating a potential upside of 113.16%. Given Gyre Therapeutics' higher possible upside, analysts clearly believe Gyre Therapeutics is more favorable than Recursion Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Gyre Therapeutics	2 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.00
Recursion Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.20

In the previous week, Recursion Pharmaceuticals had 12 more articles in the media than Gyre Therapeutics. MarketBeat recorded 12 mentions for Recursion Pharmaceuticals and 0 mentions for Gyre Therapeutics. Gyre Therapeutics' average media sentiment score of 1.87 beat Recursion Pharmaceuticals' score of 0.99 indicating that Gyre Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Gyre Therapeutics	Very Positive
Recursion Pharmaceuticals	Positive

Gyre Therapeutics has a beta of 1.9, suggesting that its stock price is 90% more volatile than the broader market. Comparatively, Recursion Pharmaceuticals has a beta of 1.04, suggesting that its stock price is 4% more volatile than the broader market.

24.0% of Gyre Therapeutics shares are held by institutional investors. Comparatively, 89.1% of Recursion Pharmaceuticals shares are held by institutional investors. 9.5% of Gyre Therapeutics shares are held by insiders. Comparatively, 8.4% of Recursion Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Gyre Therapeutics has a net margin of -5.44% compared to Recursion Pharmaceuticals' net margin of -842.95%. Gyre Therapeutics' return on equity of 3.13% beat Recursion Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Gyre Therapeutics	-5.44%	3.13%	2.67%
Recursion Pharmaceuticals	-842.95%	-54.33%	-40.60%

Summary

Gyre Therapeutics beats Recursion Pharmaceuticals on 10 of the 15 factors compared between the two stocks.

How does Gyre Therapeutics compare to HUTCHMED?

Gyre Therapeutics (NASDAQ:GYRE) and HUTCHMED (NASDAQ:HCM) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their dividends, risk, valuation, media sentiment, analyst recommendations, profitability, institutional ownership and earnings.

In the previous week, HUTCHMED had 1 more articles in the media than Gyre Therapeutics. MarketBeat recorded 1 mentions for HUTCHMED and 0 mentions for Gyre Therapeutics. Gyre Therapeutics' average media sentiment score of 1.87 beat HUTCHMED's score of 1.31 indicating that Gyre Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Gyre Therapeutics	Very Positive
HUTCHMED	Positive

Gyre Therapeutics has a beta of 1.9, suggesting that its share price is 90% more volatile than the broader market. Comparatively, HUTCHMED has a beta of 0.26, suggesting that its share price is 74% less volatile than the broader market.

24.0% of Gyre Therapeutics shares are held by institutional investors. Comparatively, 8.8% of HUTCHMED shares are held by institutional investors. 9.5% of Gyre Therapeutics shares are held by company insiders. Comparatively, 3.6% of HUTCHMED shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

HUTCHMED has a net margin of 0.00% compared to Gyre Therapeutics' net margin of -5.44%. Gyre Therapeutics' return on equity of 3.13% beat HUTCHMED's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Gyre Therapeutics	-5.44%	3.13%	2.67%
HUTCHMED	N/A	N/A	N/A

HUTCHMED has higher revenue and earnings than Gyre Therapeutics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Gyre Therapeutics	$116.59M	5.15	$5.03M	-$0.09	N/A
HUTCHMED	$548.51M	3.55	$456.91M	N/A	N/A

Gyre Therapeutics presently has a consensus price target of $17.00, indicating a potential upside of 174.64%. HUTCHMED has a consensus price target of $16.80, indicating a potential upside of 50.40%. Given Gyre Therapeutics' higher probable upside, analysts plainly believe Gyre Therapeutics is more favorable than HUTCHMED.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Gyre Therapeutics	2 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.00
HUTCHMED	1 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.40

Summary

Gyre Therapeutics beats HUTCHMED on 9 of the 15 factors compared between the two stocks.

How does Gyre Therapeutics compare to Bausch Health Cos?

Gyre Therapeutics (NASDAQ:GYRE) and Bausch Health Cos (NYSE:BHC) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their risk, analyst recommendations, valuation, profitability, dividends, institutional ownership, media sentiment and earnings.

In the previous week, Bausch Health Cos had 3 more articles in the media than Gyre Therapeutics. MarketBeat recorded 3 mentions for Bausch Health Cos and 0 mentions for Gyre Therapeutics. Gyre Therapeutics' average media sentiment score of 1.87 beat Bausch Health Cos' score of 0.16 indicating that Gyre Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Gyre Therapeutics	Very Positive
Bausch Health Cos	Neutral

Gyre Therapeutics has a beta of 1.9, suggesting that its share price is 90% more volatile than the broader market. Comparatively, Bausch Health Cos has a beta of 0.4, suggesting that its share price is 60% less volatile than the broader market.

Gyre Therapeutics currently has a consensus target price of $17.00, indicating a potential upside of 174.64%. Bausch Health Cos has a consensus target price of $8.00, indicating a potential upside of 52.53%. Given Gyre Therapeutics' stronger consensus rating and higher probable upside, equities analysts plainly believe Gyre Therapeutics is more favorable than Bausch Health Cos.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Gyre Therapeutics	2 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.00
Bausch Health Cos	1 Sell rating(s)	4 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.80

Bausch Health Cos has higher revenue and earnings than Gyre Therapeutics. Gyre Therapeutics is trading at a lower price-to-earnings ratio than Bausch Health Cos, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Gyre Therapeutics	$116.59M	5.15	$5.03M	-$0.09	N/A
Bausch Health Cos	$10.27B	0.19	$157M	-$3.24	N/A

Gyre Therapeutics has a net margin of -5.44% compared to Bausch Health Cos' net margin of -11.47%. Gyre Therapeutics' return on equity of 3.13% beat Bausch Health Cos' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Gyre Therapeutics	-5.44%	3.13%	2.67%
Bausch Health Cos	-11.47%	-2,922.77%	5.63%

24.0% of Gyre Therapeutics shares are held by institutional investors. Comparatively, 78.7% of Bausch Health Cos shares are held by institutional investors. 9.5% of Gyre Therapeutics shares are held by insiders. Comparatively, 20.7% of Bausch Health Cos shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Summary

Gyre Therapeutics beats Bausch Health Cos on 9 of the 16 factors compared between the two stocks.

How does Gyre Therapeutics compare to Trevi Therapeutics?

Gyre Therapeutics (NASDAQ:GYRE) and Trevi Therapeutics (NASDAQ:TRVI) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their earnings, media sentiment, valuation, dividends, risk, institutional ownership, analyst recommendations and profitability.

Gyre Therapeutics currently has a consensus price target of $17.00, suggesting a potential upside of 174.64%. Trevi Therapeutics has a consensus price target of $22.90, suggesting a potential upside of 64.39%. Given Gyre Therapeutics' higher possible upside, analysts plainly believe Gyre Therapeutics is more favorable than Trevi Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Gyre Therapeutics	2 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.00
Trevi Therapeutics	1 Sell rating(s)	0 Hold rating(s)	9 Buy rating(s)	2 Strong Buy rating(s)	3.00

24.0% of Gyre Therapeutics shares are held by institutional investors. Comparatively, 95.8% of Trevi Therapeutics shares are held by institutional investors. 9.5% of Gyre Therapeutics shares are held by insiders. Comparatively, 18.3% of Trevi Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

In the previous week, Trevi Therapeutics had 1 more articles in the media than Gyre Therapeutics. MarketBeat recorded 1 mentions for Trevi Therapeutics and 0 mentions for Gyre Therapeutics. Trevi Therapeutics' average media sentiment score of 1.89 beat Gyre Therapeutics' score of 1.87 indicating that Trevi Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Gyre Therapeutics	Very Positive
Trevi Therapeutics	Very Positive

Gyre Therapeutics has higher revenue and earnings than Trevi Therapeutics. Gyre Therapeutics is trading at a lower price-to-earnings ratio than Trevi Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Gyre Therapeutics	$116.59M	5.15	$5.03M	-$0.09	N/A
Trevi Therapeutics	N/A	N/A	-$42.76M	-$0.32	N/A

Gyre Therapeutics has a beta of 1.9, meaning that its stock price is 90% more volatile than the broader market. Comparatively, Trevi Therapeutics has a beta of 1.04, meaning that its stock price is 4% more volatile than the broader market.

Trevi Therapeutics has a net margin of 0.00% compared to Gyre Therapeutics' net margin of -5.44%. Gyre Therapeutics' return on equity of 3.13% beat Trevi Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Gyre Therapeutics	-5.44%	3.13%	2.67%
Trevi Therapeutics	N/A	-24.53%	-23.37%

Summary

Trevi Therapeutics beats Gyre Therapeutics on 9 of the 16 factors compared between the two stocks.

Get Gyre Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding GYRE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

GYRE vs. The Competition

Export

Metric	Gyre Therapeutics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$600.62M	$3.34B	$6.44B	$12.46B
Dividend Yield	N/A	2.37%	2.69%	5.22%
P/E Ratio	-68.77	18.78	23.87	24.36
Price / Sales	5.15	320.80	521.52	117.01
Price / Cash	25.02	110.40	41.27	57.13
Price / Book	4.18	6.80	9.99	6.73
Net Income	$5.03M	$24.09M	$3.56B	$337.03M
7 Day Performance	7.84%	-2.56%	-0.89%	0.09%
1 Month Performance	N/A	N/A	N/A	-1.78%
1 Year Performance	-27.86%	48.90%	28.76%	33.98%

Gyre Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
GYRE Gyre Therapeutics	2.4431 of 5 stars	$6.19 +8.8%	$17.00 +174.6%	-30.8%	$600.62M	$116.59M	N/A	40	Positive News
RARE Ultragenyx Pharmaceutical	2.8155 of 5 stars	$21.78 -4.7%	$59.56 +173.5%	-38.4%	$2.25B	$673M	N/A	1,371	Insider Trade
RXRX Recursion Pharmaceuticals	2.9377 of 5 stars	$3.61 -4.7%	$8.10 +124.4%	-21.0%	$2.01B	$74.68M	N/A	400	Insider Trade
HCM HUTCHMED	3.9537 of 5 stars	$11.52 +1.1%	$16.80 +45.8%	-23.1%	$1.99B	$548.51M	N/A	1,796	Positive News High Trading Volume
BHC Bausch Health Cos	3.13 of 5 stars	$5.03 -5.4%	$8.00 +59.2%	+8.2%	$1.98B	$10.27B	N/A	20,300	Gap Up High Trading Volume

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:GYRE) was last updated on 6/4/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Gyre Therapeutics (GYRE) Competitors

GYRE vs. RARE, RXRX, HCM, BHC, and TRVI

How does Gyre Therapeutics compare to Ultragenyx Pharmaceutical?

Summary

How does Gyre Therapeutics compare to Recursion Pharmaceuticals?

Summary

How does Gyre Therapeutics compare to HUTCHMED?

Summary

How does Gyre Therapeutics compare to Bausch Health Cos?

Summary

How does Gyre Therapeutics compare to Trevi Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

GYRE vs. The Competition

Gyre Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Gyre Therapeutics (GYRE) Competitors

GYRE vs. RARE, RXRX, HCM, BHC, and TRVI

How does Gyre Therapeutics compare to Ultragenyx Pharmaceutical?

Do institutionals and insiders believe in RARE or GYRE?

Which has preferable valuation & earnings, RARE or GYRE?

Does the media refer more to RARE or GYRE?

Which has more volatility and risk, RARE or GYRE?

Is RARE or GYRE more profitable?

Do analysts rate RARE or GYRE?

Summary

How does Gyre Therapeutics compare to Recursion Pharmaceuticals?

Which has better valuation & earnings, GYRE or RXRX?

Do analysts prefer GYRE or RXRX?

Does the media prefer GYRE or RXRX?

Which has more risk and volatility, GYRE or RXRX?

Do insiders and institutionals have more ownership in GYRE or RXRX?

Is GYRE or RXRX more profitable?

Summary

How does Gyre Therapeutics compare to HUTCHMED?

Does the media favor GYRE or HCM?

Which has more risk & volatility, GYRE or HCM?

Do insiders & institutionals have more ownership in GYRE or HCM?

Is GYRE or HCM more profitable?

Which has higher earnings and valuation, GYRE or HCM?

Do analysts prefer GYRE or HCM?

Summary

How does Gyre Therapeutics compare to Bausch Health Cos?

Does the media favor GYRE or BHC?

Which has more volatility & risk, GYRE or BHC?

Do analysts prefer GYRE or BHC?

Which has preferable valuation and earnings, GYRE or BHC?

Is GYRE or BHC more profitable?

Do institutionals and insiders have more ownership in GYRE or BHC?

Summary

How does Gyre Therapeutics compare to Trevi Therapeutics?

Do analysts prefer GYRE or TRVI?

Do institutionals & insiders hold more shares of GYRE or TRVI?

Does the media refer more to GYRE or TRVI?

Which has higher valuation & earnings, GYRE or TRVI?

Which has more risk and volatility, GYRE or TRVI?

Is GYRE or TRVI more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

GYRE vs. The Competition

Gyre Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools